FDA takes steps to boost generic competition, limit prices

Credit: CC0 Public Domain

The Food and Drug Administration is taking steps to boost the number of generic prescription drugs in an effort to make medicines more affordable and to prevent price gouging.

Copycat pills normally are much cheaper than original brand-name drugs. But in some cases, when a generic has no competition, companies have drastically increased .

New commissioner Dr. Scott Gottlieb said Tuesday that the FDA will now give priority reviews to new generic drugs until there are at least three on the market. That's the level at which prices tend to drop sharply, up to 85 percent off the brand-name price.

The agency also published its first list of brand-name drugs that no longer have a patent's protection but don't yet have .

© 2017 The Associated Press. All rights reserved.

Citation: FDA takes steps to boost generic competition, limit prices (2017, June 27) retrieved 12 April 2024 from https://medicalxpress.com/news/2017-06-fda-boost-competition-limit-prices.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

High court ruling speeds up generic biotech drug approval


Feedback to editors